318 related articles for article (PubMed ID: 26481928)
1. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
Mulenga V; Musiime V; Kekitiinwa A; Cook AD; Abongomera G; Kenny J; Chabala C; Mirembe G; Asiimwe A; Owen-Powell E; Burger D; McIlleron H; Klein N; Chintu C; Thomason MJ; Kityo C; Walker AS; Gibb DM;
Lancet Infect Dis; 2016 Feb; 16(2):169-79. PubMed ID: 26481928
[TBL] [Abstract][Full Text] [Related]
2. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
Munderi P; Walker AS; Kityo C; Babiker AG; Ssali F; Reid A; Darbyshire JH; Grosskurth H; Mugyenyi P; Gibb DM; Gilks CF;
HIV Med; 2010 May; 11(5):334-44. PubMed ID: 20136661
[TBL] [Abstract][Full Text] [Related]
3. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
[TBL] [Abstract][Full Text] [Related]
4. Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial.
Paediatric European Network for Treatment of AIDS (PENTA)
Lancet; 2002 Mar; 359(9308):733-40. PubMed ID: 11888583
[TBL] [Abstract][Full Text] [Related]
5. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial.
ARROW Trial team
Lancet; 2013 Apr; 381(9875):1391-1403. PubMed ID: 23473847
[TBL] [Abstract][Full Text] [Related]
6. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
[TBL] [Abstract][Full Text] [Related]
7. Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
Shey MS; Kongnyuy EJ; Alobwede SM; Wiysonge CS
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD005481. PubMed ID: 23543540
[TBL] [Abstract][Full Text] [Related]
8. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects.
Staszewski S; Katlama C; Harrer T; Massip P; Yeni P; Cutrell A; Tortell SM; Harrigan RP; Steel H; Lanier RE; Pearce G
AIDS; 1998 Nov; 12(16):F197-202. PubMed ID: 9833847
[TBL] [Abstract][Full Text] [Related]
9. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.
Green H; Gibb DM; Walker AS; Pillay D; Butler K; Candeias F; Castelli-Gattinara G; Compagnucci A; Della Negra M; de Rossi A; Feiterna-Sperling C; Giaquinto C; Harper L; Levy J; Saidi Y; Wintergerst U;
AIDS; 2007 May; 21(8):947-55. PubMed ID: 17457088
[TBL] [Abstract][Full Text] [Related]
10. Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA).
Dart Trial Team
Trop Med Int Health; 2008 Jan; 13(1):6-16. PubMed ID: 18290996
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysis.
Adetokunboh OO; Schoonees A; Balogun TA; Wiysonge CS
BMC Infect Dis; 2015 Oct; 15():469. PubMed ID: 26502899
[TBL] [Abstract][Full Text] [Related]
12. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS
HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316
[TBL] [Abstract][Full Text] [Related]
13. Once vs twice-daily abacavir and lamivudine in African children.
Musiime V; Kasirye P; Naidoo-James B; Nahirya-Ntege P; Mhute T; Cook A; Mugarura L; Munjoma M; Thoofer NK; Ndashimye E; Nankya I; Spyer MJ; Thomason MJ; Snowden W; Gibb DM; Walker AS;
AIDS; 2016 Jul; 30(11):1761-70. PubMed ID: 27064996
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Bravenboer B; Ten Kate RW; Groeneveld P; Bierman W; van der Werf Ts; Gisolf E; Richter C
HIV Med; 2015 Feb; 16(2):122-31. PubMed ID: 25472825
[TBL] [Abstract][Full Text] [Related]
15. Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial.
Musiime V; Cook A; Kayiwa J; Zangata D; Nansubuga C; Arach B; Kenny J; Wavamunno P; Komunyena J; Kabamba D; Asiimwe AR; Mirembe G; Abongomera G; Mulenga V; Kekitiinwa A; Kityo C; Walker SA; Klein N; Gibb DM;
Antivir Ther; 2014; 19(3):269-76. PubMed ID: 24717427
[TBL] [Abstract][Full Text] [Related]
16. Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa.
Palmer M; Chersich M; Moultrie H; Kuhn L; Fairlie L; Meyers T
AIDS; 2013 Mar; 27(5):781-5. PubMed ID: 23169331
[TBL] [Abstract][Full Text] [Related]
17. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial.
BREATHER (PENTA 16) Trial Group
Lancet HIV; 2016 Sep; 3(9):e421-e430. PubMed ID: 27562743
[TBL] [Abstract][Full Text] [Related]
18. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
Ruane PJ; Parenti DM; Margolis DM; Shepp DH; Babinchak TJ; Van Kempen AS; Kauf TL; Danehower SA; Yau L; Hessenthaler SM; Goodwin D; Hernandez JE;
HIV Clin Trials; 2003; 4(4):231-43. PubMed ID: 12916008
[TBL] [Abstract][Full Text] [Related]
19. First-line antiretroviral drug discontinuations in children.
Fortuin-de Smidt M; de Waal R; Cohen K; Technau KG; Stinson K; Maartens G; Boulle A; Igumbor EU; Davies MA
PLoS One; 2017; 12(2):e0169762. PubMed ID: 28192529
[TBL] [Abstract][Full Text] [Related]
20. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine.
Gerstoft J; Kirk O; Obel N; Pedersen C; Mathiesen L; Nielsen H; Katzenstein TL; Lundgren JD
AIDS; 2003 Sep; 17(14):2045-52. PubMed ID: 14502007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
